Constellation Pharmaceuticals Financial Statements (CNST)
|
|
|
|
Report date
|
|
|
31.12.2016 |
31.12.2017 |
14.03.2019 |
10.03.2020 |
24.02.2021 |
|
10.05.2021 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-33.7 |
-39.1 |
-61.2 |
-86.1 |
-124.8 |
|
-139.1 |
|
EBITDA, bln rub |
? |
|
-33.0 |
-34.0 |
-59.1 |
-82.7 |
-122.8 |
|
-138.2 |
|
Net profit, bln rub |
? |
|
-34.5 |
-35.4 |
-59.9 |
-85.6 |
-126.4 |
|
-141.0 |
|
|
OCF, bln rub |
? |
|
-32.8 |
-37.6 |
-48.8 |
-72.2 |
-111.4 |
|
-125.1 |
|
CAPEX, bln rub |
? |
|
0.948 |
0.582 |
0.476 |
0.699 |
0.946 |
|
1.40 |
|
FCF, bln rub |
? |
|
-33.7 |
-38.2 |
-49.3 |
-72.9 |
-112.4 |
|
-126.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
33.7 |
39.1 |
61.2 |
86.1 |
124.8 |
|
139.1 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
27.9 |
32.6 |
48.8 |
66.5 |
95.5 |
|
106.2 |
|
Interest expenses, bln rub |
|
|
1.35 |
0.901 |
0.228 |
2.12 |
2.86 |
|
2.01 |
|
|
Assets, bln rub |
|
|
38.7 |
19.1 |
118.9 |
399.1 |
441.9 |
|
402.7 |
|
Net Assets, bln rub |
? |
|
17.3 |
7.40 |
104.2 |
337.6 |
410.7 |
|
377.3 |
|
Debt, bln rub |
|
|
10.6 |
4.10 |
0.000 |
32.2 |
4.23 |
|
3.37 |
|
Cash, bln rub |
|
|
36.9 |
16.4 |
114.6 |
383.9 |
421.4 |
|
382.1 |
|
Net debt, bln rub |
|
|
-26.3 |
-12.3 |
-114.6 |
-351.7 |
-417.2 |
|
-378.7 |
|
|
Ordinary share price, rub |
|
|
|
|
4.01 |
47.1 |
28.8 |
|
34.0 |
|
Number of ordinary shares, mln |
|
|
48.0 |
11.7 |
12.0 |
28.2 |
28.2 |
|
47.8 |
|
|
Market cap, bln rub |
|
|
0 |
0 |
48 |
1 326 |
811 |
|
1 624 |
|
EV, bln rub |
? |
|
-26 |
-12 |
-67 |
974 |
394 |
|
1 245 |
|
Book value, bln rub |
|
|
17 |
7 |
104 |
338 |
411 |
|
377 |
|
|
EPS, rub |
? |
|
-0.72 |
-3.03 |
-5.00 |
-3.04 |
-4.49 |
|
-2.95 |
|
FCF/share, rub |
|
|
-0.70 |
-3.27 |
-4.11 |
-2.59 |
-3.99 |
|
-2.64 |
|
BV/share, rub |
|
|
0.36 |
0.63 |
8.69 |
12.0 |
14.6 |
|
7.89 |
|
|
FCF yield, % |
? |
|
|
|
-102.6% |
-5.50% |
-13.9% |
|
-7.79% |
|
ROE, % |
? |
|
-199.3% |
-478.4% |
-57.5% |
-25.3% |
-30.8% |
|
-37.4% |
|
ROA, % |
? |
|
-89.2% |
-185.2% |
-50.4% |
-21.4% |
-28.6% |
|
-35.0% |
|
|
P/E |
? |
|
0.00 |
0.00 |
-0.80 |
-15.5 |
-6.42 |
|
-11.5 |
|
P/FCF |
|
|
0.00 |
0.00 |
-0.97 |
-18.2 |
-7.22 |
|
-12.8 |
|
P/BV |
? |
|
0.00 |
0.00 |
0.46 |
3.93 |
1.97 |
|
4.30 |
|
EV/EBITDA |
? |
|
0.80 |
0.36 |
1.13 |
-11.8 |
-3.20 |
|
-9.01 |
|
Debt/EBITDA |
|
|
0.80 |
0.36 |
1.94 |
4.26 |
3.40 |
|
2.74 |
|
|
R&D/CAPEX, % |
|
|
2 941% |
5 604% |
10 246% |
9 508% |
10 095% |
|
7 597% |
|
| Constellation Pharmaceuticals shareholders |
